AUTHORS
Upasana Ray, PhD, Minghao Dang, PhD2, Jun Wei, MD, PhD3, Isere Kuiatse, PhD4, Sherif Seif, MD5, Maria Jose Acevedo-Calado, PhD6, Hima Bansal, MBBS7, Sheeba Koshy Thomas, M.D.8, Robert Orlowski, MD, PhD9
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: Waldenström macroglobulinemia (WM) is a non-Hodgkin lymphoma characterized by coexistence of distinct tumor cell phenotypes, ranging from CD19+ B cells to CD138+ plasma cells (PCs). Due to existing heterogeneity, it remains incurable, with increasing incidence. At the molecular level, ~90% of WM patients harbor a somatic L265P mutation in Myeloid differentiation primary response gene 88 (MYD88). Considering key genomic changes, Bruton's tyrosine kinase inhibitors (BTKis), which work downstream of MYD88, used alone or with rituximab (anti-CD20), are the only FDA-approved options for WM. However, complete remission is rare, with limitations in development of BTKi resistance, posing an emerging treatment challenge. There is thus an urgent need to develop novel targeted therapies to improve outcomes in WM. We included our database of paired single-cell RNA sequencing (scRNA-Seq) and B-cell receptor sequencing (scBCR-Seq) data from 79 freshly collected bone marrow aspirate samples from smoldering WM (n=16), untreated symptomatic WM (n=15), and previously treated WM (n=48) to analyze the transcriptional profiles that were modulated. Differential gene expression analysis identified key up- and down-regulated genes in both CD19+ and CD138+ cells that could be putative oncogenes and tumor suppressors, respectively, by comparing neoplastic cells identified by their clonal variable-diversity-joining (V(D)J) sequence to each patient’s own normal cells as controls. We found that TNFRSF13B (transmembrane activator and calcium-modulating cyclophilin ligand interactor, TACI) was consistently increased in both neoplastic B cells and PCs. TACI, crucial for B cell activation and differentiation, was priorly shown to play a critical role in tumor progression, making it a promising target for WM therapies. We sought to delineate the antitumor efficacy of a TACI-targeted antibody-drug conjugate (ADC) in preclinical in vitro and in vivo WM models.
Methods: Expression of TACI was determined in cell lines by flow cytometry. We used biotinylated anti-human TACI (anti-BioTACI) and Streptavidin-MMAE (S-MMAE), which were pre-incubated together for 20 mins at same molar ratio to form an ADC. Cell viability was measured at 72 hrs after treatment in a dose-dependent manner. Apoptosis was evaluated by Annexin-V/PI staining using flow cytometry at 48 hrs post-treatment. Immunoblot analysis assessed the expression of cleaved caspase-3 and cleaved Poly(ADP-ribose) polymerase (PARP1) following treatment. Clonogenic assays were performed by mixing cells with Matrigel and incubating at 37°C. After solidification, medium with ADC and control treatments was added. A NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse xenograft was used to assess the efficacy of the ADC. Luciferase+ WM cells were injected intravenously, and on day 7, mice were randomized based on disease burden and injected with PBS, S-MMAE, anti-BioTACI, and ADC at 1mg/kg (n=7). Tumor progression monitored.
Results: Cell surface TACI expression was found in WM and selected MM cell lines. We evaluated cell viability in TACI+ WM cell lines and TACI- (NCI-H929) cells after 72 hrs of treatment with ADCs, using S-MMAE and anti-BioTACI as controls. Neither S-MMAE nor anti-BioTACI affected cell viability, whereas the TACI ADC reduced WM cell viability, with no activity observed in NCI-H929. A significant increase in apoptotic events was observed in WM cells treated with 5 and 10 nM ADC for 48 hrs compared to controls, also validated by increased levels of cleaved caspase-3 and cleaved PARP1. In the Matrigel clonogenic assay, control treatments did not affect colony formation, whereas 10 nM ADC significantly reduced colony formation. Our in vivo validation in the NSG xenograft model using RPCI-WM1-luciferase+ cells showed significant tumor regression in the ADC-treated cohort compared to control groups.
Conclusion: Our results highlight TACI as a promising immunotherapy target in WM, given its consistent upregulation in both neoplastic B cells and PCs. This helps to address the complex, dynamic heterogeneity that undermines the effectiveness of current therapeutic regimens in WM. Our findings show the efficacy of TACI ADCs in preclinical WM models and establish a strong therapeutic foundation for evaluating immunotherapeutic approaches to improve patient outcomes. Moving forward, we will validate the efficacy of ADCs in primary tumor cells from WM patients and in patient-derived xenograft models.
DISCLOSURES
Upasana Ray, PhD: No relevant conflicts of interest to declare.